NSAID-GASTRODUODENOPATHIES IN PATIENTS WITH OSTEOARTHRITIS: PECULIARITIES OF DIAGNOSTICS, PREVENTION AND TREATMENT
https://doi.org/10.14412/1995-4484-2002-1213
Abstract
Objective. To improve both prophylaxis and treatment of NSA ID-associated gastroduodenopathies in osteoar- thritic patients. Material and methods. The study included 155 osieoarthritic pts., NSAID-therapy included ibuprofen, meloxi- cam or different forms of diclofenac. Endoscopy before investigation, on the 4-5"' day and on the 3 ,J week (with gastrobiopsy in 37) was performed, as well as basal intragastric pH study (in 57), basal cortisolemia level - immunoassay (in 124). Diagnosis of Helicobacter pylori (in 88) by ELISA and biochemical methods. Results. Taking into account both NSAID-therapy duration and its methods used, the risk-factors presented, patients’ Helicobacter pylori-status and their adrenal glands’ cortisol-productive function, it has been described the frequency of the revealed erosive-and-ulcerous lesions, as well as their clinical and endoscopic peculiarities. The efficacy of ulcers monotherapy with misoprostol has been evaluated. Conclusion. It is expedient first local, then prostaglandin-dependent gastroprotection while taking NSAID, both in Hp-negative and positive pts. Concomitant Helicobacter pylori-infection does not worsen 3-week NSAID- therapy gastric tolerability, but hypercortisolemia does so. Misoprostol proved to be expedient in ulserous gas- troduodcnopathy .
References
1. <div><p>Арунн Л.И,, Капуллер Л.Л., Исаков В.А. Морфологическая диагностика болезней желудка и кишечника. М., Триада-Х, 1998.</p><p>Астапенко М.Г. Копьева Т.Н., Дуляинн В.А. и др. Клиниколабораторная характеристики синовнта при деформирующем остеоартрозе. Ревматол., 1984, 4, 10-14.</p><p>Астапенко М.Г. и соапт Клинические формы и варианты течения первичного деформирующего остеоартроза. Ревматол., 1986,4, 10-13.</p><p>Biктopoв О.П., Гололихо Л.1., Рибак О.Т. Побочна д'ю несте- рощиих протнзапапьних лисарських засоб1в. В: Мат. II Нац. Конгр. ревматол., Украши. - Кшв, 1997, 10.</p><p>Григорьев П.Я., Яковенко Э.П. Повреждения желудка и двенадцатиперстной кишки при лечении нестероидными противовоспалительными препаратами, Клин, медицина, 1997.3,6971.</p><p>Заболотных И.И. Первичный деформирующий остеоартроз: клиника, диагностика, лечение, экспертиза трудоспособности.Ленинград, Наука, 1988.</p><p>Каратеев А.Е., Насонова В.А., Муравьев Ю.В. Оценка влияния глюкокортпкостсроидных и нсстероидных противовоспалительных препаратов на развитие эрозивно-язвенного поражения желудочно-кишечного тракта у больных с ревматическими заболеваниями. Тер. архив 1999, 2, 26-30.</p><p>Насонова В.А. Диагностика и лечение больных пожилою возраста, страдающих манифестным остеоартрозом. Рус. мед. журнал, 2001, 3-4, 157-160.</p><p>Насонов Е.Л. Нестерондные противовоспалительные препараты при ревматических заболеваниях: стандарт лечения. Рус. мед. журнал, 2001, 7-8, 265-270,</p><p>Хитров Н.А., Цурко В.В., Сильвестров В.П., Семочкина Е.Н. Патогенетическое лечение болевого синдрома при остеоартрозе. Рос. мед. журнал, 2001, 1, 45-49.</p><p>Altman R. Criteria for classification оГclinical osteoarthritis. Miami, Florida, USA. EULAR Bulletin, 1992, 3,73-74.</p><p>Beejay U., Wolfe M.M. Cyclooxygenase 2-selcctivc inhibitors: pan- асеаог flash in the pan? (Editorial). Gastroenterol., 1999,117,10021005.</p><p>Bianchi Porro G„ Parente F., Imbesi V. et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSA1D users. Responce to omeprasol dual therapy. Gut, 1996, 39(1), 22-26.</p><p>Graham D.Y. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori and ulcers: where we stand. Am.J.Gastroenterol., 1996, 91 (10), 2080-2086.</p><p>Hawkey C.J., Swannell A.J., Yeomans N.D. et al. Site-specific ulcer relapse in nonsteroidal anti-inflammatory drug (NSAID) users: improved prognosis with Helicobacter pylori and with ome- prasole compared with misoprostol. Gut, 1996, suppl.3, 842.</p><p>Kellgren G.H., Lawrence J.S. Radiological assessment of osteoarthrosis. Ann. Rheum., 1957, 16,494-501.</p><p>Konlurek J.W., Konturek S.J., Stachura J„ Domschke W. Helicobacter pylori positive duodenal ulcer patients do not adapt to aspirin. In: Xlth International Workshop on Gastroduodenal Pathology and H.Pylori. Sept. 2-5, 1998, Budapest, abst. 13/367. IS. Persico М., Suozzo R., Tussilo C. et al. Decreased gastroduodenal concentration of transforming growth factor alpha in Helicobacter pylori-infected dyspeptic patients. In: Xlth International Workshop on Gastroduodenal Pathology and H.Pylori. SepL. 2-5, 1998, Budapest, abst.t 02/63.</p><p>Roth S.H. Nonsteroidal anti-inflammatory drug gastropathy. Arch. Intern. Med., 1986, 146(10), 1075-1076.</p><p>Skeljo M.V., Cook G.A., Elliott S.L. el al. Gastric mucosal adaptation to Diclofenac injury. Dig. Dis. Sci., 1996, 41 (I), 32-39.</p><p>Silverstein F.E. New strategies for prevention of serious upper G1 complications from NSAIDs: lessons from the mucosa trial. New Standarts Arthr. Care, 1996, 5(1), 2-6.</p><p>Singh G., Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J. Rheumatol., 1998, 26, 18-24.</p><p>Waki S., Kinoshita Y., Fukui H. et al, Intragastric distribution of non-steroidal anti-inflammatory drugs-related ulcers in patients without collagen diseases. J.Clin. Gastroenterol., 1997,25,592-594.</p><p>Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 1999, 340(24), 1888-1899.</p><p>Yeomans N.D., Cook G.A., Giraud A.S. Selective COX-2 inhibitors: are they safe for the stomach? Gastroenterol., 1998, I IS (I), 227-229.</p></div><br />
Review
For citations:
Svintzitzky A.S., Puzcmova O.G. NSAID-GASTRODUODENOPATHIES IN PATIENTS WITH OSTEOARTHRITIS: PECULIARITIES OF DIAGNOSTICS, PREVENTION AND TREATMENT. Rheumatology Science and Practice. 2002;40(3):26-31. (In Russ.) https://doi.org/10.14412/1995-4484-2002-1213
Views:
817
Email this article 